NasdaqGM:ATAIPharmaceuticals
Why AtaiBeckley (ATAI) Is Up 29.3% After New Data And Psychedelic Policy Tailwinds – And What's Next
AtaiBeckley Inc. recently published peer‑reviewed Phase 2a data showing that a single intranasal dose of BPL-003 produced rapid, sustained reductions in depression scores for treatment‑resistant patients on stable SSRI therapy, while also confirming plans to begin Phase 3 trials following FDA End‑of‑Phase 2 alignment.
On the policy front, a new US executive order instructing regulators to prioritize psychedelic drugs with Breakthrough Therapy designation and expand Right to Try access could...